Newer agents in colon cancer: What's next?

Belisario A. Arango, Ikechukwu Akunyili

Research output: Contribution to journalArticle

Abstract

Colorectal cancer (CRC) was the third leading cause of cancer deaths in the United States in 2012, and most patients eventually develop metastatic disease. The use of cytotoxic chemotherapy, the antiangiogenesis drug bevacizumab, and the anti-EGFR monoclonal antibodies cetuximab and panitumumab have led to an improvement in median OS for metastatic CRC. Despite this improvement in survival, few agents have activity against CRC. Between 2006 and 2012, the FDA approved no new agents for patients with metastatic CRC (mCRC). Recently, the FDA has approved aflibercept and regorafenib for use in the treatment of patients with mCRC, and several new agents are currently in development. This paper reviews the use of new agents and new uses for established agents in mCRC.

Original languageEnglish
Pages (from-to)74-84
Number of pages11
JournalCurrent Colorectal Cancer Reports
Volume9
Issue number1
DOIs
StatePublished - Jan 24 2013

Fingerprint

Colonic Neoplasms
Colorectal Neoplasms
Proxy
Cause of Death
Monoclonal Antibodies
Drug Therapy
Survival
Pharmaceutical Preparations
Neoplasms
Therapeutics

Keywords

  • Aflibercept
  • Antiangiogenesis
  • Bevacizumab
  • Colorectal cancer
  • Cytotoxic chemotherapy
  • Regorafenib

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Hepatology

Cite this

Newer agents in colon cancer : What's next? / Arango, Belisario A.; Akunyili, Ikechukwu.

In: Current Colorectal Cancer Reports, Vol. 9, No. 1, 24.01.2013, p. 74-84.

Research output: Contribution to journalArticle

Arango, Belisario A. ; Akunyili, Ikechukwu. / Newer agents in colon cancer : What's next?. In: Current Colorectal Cancer Reports. 2013 ; Vol. 9, No. 1. pp. 74-84.
@article{2ba6dc397b1c437882e4a34008b0289c,
title = "Newer agents in colon cancer: What's next?",
abstract = "Colorectal cancer (CRC) was the third leading cause of cancer deaths in the United States in 2012, and most patients eventually develop metastatic disease. The use of cytotoxic chemotherapy, the antiangiogenesis drug bevacizumab, and the anti-EGFR monoclonal antibodies cetuximab and panitumumab have led to an improvement in median OS for metastatic CRC. Despite this improvement in survival, few agents have activity against CRC. Between 2006 and 2012, the FDA approved no new agents for patients with metastatic CRC (mCRC). Recently, the FDA has approved aflibercept and regorafenib for use in the treatment of patients with mCRC, and several new agents are currently in development. This paper reviews the use of new agents and new uses for established agents in mCRC.",
keywords = "Aflibercept, Antiangiogenesis, Bevacizumab, Colorectal cancer, Cytotoxic chemotherapy, Regorafenib",
author = "Arango, {Belisario A.} and Ikechukwu Akunyili",
year = "2013",
month = "1",
day = "24",
doi = "10.1007/s11888-012-0157-y",
language = "English",
volume = "9",
pages = "74--84",
journal = "Current Colorectal Cancer Reports",
issn = "1556-3790",
publisher = "Springer Science + Business Media",
number = "1",

}

TY - JOUR

T1 - Newer agents in colon cancer

T2 - What's next?

AU - Arango, Belisario A.

AU - Akunyili, Ikechukwu

PY - 2013/1/24

Y1 - 2013/1/24

N2 - Colorectal cancer (CRC) was the third leading cause of cancer deaths in the United States in 2012, and most patients eventually develop metastatic disease. The use of cytotoxic chemotherapy, the antiangiogenesis drug bevacizumab, and the anti-EGFR monoclonal antibodies cetuximab and panitumumab have led to an improvement in median OS for metastatic CRC. Despite this improvement in survival, few agents have activity against CRC. Between 2006 and 2012, the FDA approved no new agents for patients with metastatic CRC (mCRC). Recently, the FDA has approved aflibercept and regorafenib for use in the treatment of patients with mCRC, and several new agents are currently in development. This paper reviews the use of new agents and new uses for established agents in mCRC.

AB - Colorectal cancer (CRC) was the third leading cause of cancer deaths in the United States in 2012, and most patients eventually develop metastatic disease. The use of cytotoxic chemotherapy, the antiangiogenesis drug bevacizumab, and the anti-EGFR monoclonal antibodies cetuximab and panitumumab have led to an improvement in median OS for metastatic CRC. Despite this improvement in survival, few agents have activity against CRC. Between 2006 and 2012, the FDA approved no new agents for patients with metastatic CRC (mCRC). Recently, the FDA has approved aflibercept and regorafenib for use in the treatment of patients with mCRC, and several new agents are currently in development. This paper reviews the use of new agents and new uses for established agents in mCRC.

KW - Aflibercept

KW - Antiangiogenesis

KW - Bevacizumab

KW - Colorectal cancer

KW - Cytotoxic chemotherapy

KW - Regorafenib

UR - http://www.scopus.com/inward/record.url?scp=84873706921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873706921&partnerID=8YFLogxK

U2 - 10.1007/s11888-012-0157-y

DO - 10.1007/s11888-012-0157-y

M3 - Article

AN - SCOPUS:84873706921

VL - 9

SP - 74

EP - 84

JO - Current Colorectal Cancer Reports

JF - Current Colorectal Cancer Reports

SN - 1556-3790

IS - 1

ER -